Porsolt has opened a new preclinical contract research facility in San Antonio, TX. The facility will be operational in October 2010 under full AAALAC accreditation, and will provide non-GLP and GLP specialist pharmacology services to the global pharma and biotech industries. Services will initially focus on abuse liability assessment of new Chemical and Biological Entities (NCEs and NBEs) in non-human primates, as well as will include those provided by the parent company headquartered in France.

Dr. Roger D. Porsolt, president and founder of Porsolt, said, “Possessing our own Research Centre in the U.S. fulfils a longstanding ambition to provide services to our expanding list of US sponsors. Since our inception over 25 years ago, we have sought to establish ourselves as internationally recognized scientific experts in pharmacology and have already had considerable success in attracting North American clients. Possessing our own research site on the North American continent will reinforce this and should open the way for U.S. public bodies and private U.S. research foundations to benefit from our services. Although our initial thrust will be in the area of drug abuse/dependence, we intend to expand rapidly to cover other major medical areas including cognitive, pain, inflammatory, schizophrenia, respiratory and cardiovascular pharmacology.”